Ibutamoren
Ibutamoren is not a peptide. It is indexed alongside Growth hormone secretagogues because it appears in the same research literature and the same search demand; no statement on this site describes it as a peptide.
Identity
| Field | Value |
|---|---|
| Classification | Not a peptide |
| Primary class | Growth hormone secretagogues |
| CAS registry number | 159634-47-6[1] |
| PubChem CID | 178024[1] |
| UniProt accession | Unknown No UniProt query was run in v1. |
| Molecular formula | C27H36N4O5S[1] |
| Molecular weight | 528.7 g/mol[1] |
| Amino-acid sequence | Unknown Not reported by the PubChem property set retrieved for this record; no sequence database query was run in v1. |
| Reported half-life | Unknown No pharmacokinetics source was retrieved in v1. PubChem does not carry half-life as a property, so this is recorded as not yet sourced rather than estimated. |
What the cited literature examines
Ibutamoren is a non-peptide growth hormone secretagogue and is included in this dataset because it is researched and searched alongside the peptide secretagogues. It is not a peptide, and the is_peptide field on this record is false. A 2001 Clinical Pharmacology and Therapeutics paper describes it explicitly as a nonpeptide growth hormone secretagogue given orally.
A 2021 Nature Communications paper reports the structural basis of human ghrelin receptor signalling by ghrelin and by the synthetic agonist ibutamoren. A 2011 paper in Archives of Gerontology and Geriatrics reports a multicentre study in patients recovering from hip fracture, and a 2022 Rapid Communications in Mass Spectrometry paper characterises the compound and its metabolites for doping-control purposes.
[3, 4, 5, 6]Reported mechanism
A non-peptide agonist at the ghrelin receptor, the growth hormone secretagogue receptor.
[4, 3]Stated in the titles of the cited 2021 Nature Communications and 2001 Clinical Pharmacology and Therapeutics papers.
Targets named in the cited records: growth hormone secretagogue receptor.
FDA application register
A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.[2]
Scope statement: this records the result of a single automated query against the openFDA drugsfda endpoint on the stated date. It is not legal advice and is not a jurisdiction-by-jurisdiction legality assessment.
Retrieved 2026-10-09.
Amounts reported in the cited literature
Unknown. No retrieved record in this dataset states an amount, so none is shown. Where an amount is recorded it is what a named study reported administering in its own stated model, in the past tense, and is not a protocol.
No study-reported dose was taken from a source read in v1. Literature-reported values are only recorded where the retrieved citation metadata states the figure.
Adverse effects reported in the cited literature
Unknown. No retrieved record in this dataset reports an adverse effect for this compound, so no row is shown. Absence of a row records the absence of a retrieved report, nothing more.
No adverse-effect row was taken from a source read in v1. Rows are only recorded with the study model named and the reporting citation attached.
Other names
Ibutamoren appears under these other names in the cited records or in common usage. Each one resolves to this page rather than to a separate page of its own.
- MK-677
- MK-0677
- ibutamoren mesylate
Where this page sits
Research records
Cited research records for Ibutamoren, each with its identifier, the publication type it is indexed as, and the study model stated by its assigned subject headings.
Compounds indexed next to it
- Ipamorelin — Growth hormone secretagogues
- GHRP-6 — Growth hormone secretagogues
- Hexarelin — Growth hormone secretagogues
- Capromorelin — Growth hormone secretagogues
- Ghrelin — Growth hormone secretagogues
Named targets in the cited records
Class page: Growth hormone secretagogues. Full index: all indexed compounds.
Questions this page answers
What does the cited literature examine for Ibutamoren?
Ibutamoren is a non-peptide growth hormone secretagogue and is included in this dataset because it is researched and searched alongside the peptide secretagogues. It is not a peptide, and the is_peptide field on this record is false.
Which class is Ibutamoren indexed under?
Ibutamoren is indexed under Growth hormone secretagogues. Growth hormone secretagogues are compounds that act at the growth hormone secretagogue receptor, the receptor for ghrelin, rather than at the growth hormone releasing hormone receptor.
What does the FDA application register show for Ibutamoren?
A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.
Sources
- PubChem Compound Summary for CID 178024, Ibutamoren. PubChem, National Library of Medicine (2026). pubchem:178024
- Drugs@FDA application register query for this compound, no application records returned. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:ibutamoren
- Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormone-insulin-like growth factor I axis in growth hormone-deficient children. Clin Pharmacol Ther (2001). pmid:11452249
- Structural basis of human ghrelin receptor signaling by ghrelin and the synthetic agonist ibutamoren. Nat Commun (2021). pmid:34737341
- MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study. Arch Gerontol Geriatr (2011). pmid:21067829
- Characterization of growth hormone secretagogue small molecule ibutamoren (MK-0677) and its possible metabolites in thoroughbred horses for doping control. Rapid Commun Mass Spectrom (2022). pmid:35716382
On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.